Roche Inks A Second Deal With PTC Therapeutics, Pays $30M Upfront
This article was originally published in The Pink Sheet Daily
The Big Pharma teams up with a biotech and a patient advocacy foundation to develop treatments for a rare genetic disorder.
You may also be interested in...
PTC Adds To Management Team In Sign Of Progress Beyond Setbacks
The New Jersey-based biotech has not lost its optimism after a setback in Europe for its lead product and is showing growth in other areas.
Isis Moves SMA Drug Forward As Market Interest For The Rare Disease Expands
Spinal muscular atrophy is a rare disease that affects a small patient population of children. Isis is ready to move its compound into mid-stage testing after positive Phase I results, but the biotech isn’t the only company exploring the field.
Deals of the Week: Sanofi/Joslin; Merck/Ambrx; Genentech/AC Immune; GSK/Liquidia; Roche/Seaside
Walgreens’ deal to acquire Alliance Boots vastly expands its international presence but got a chilly reception on Wall Street.